Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 669.

https://doi.org/10.1182/blood-2023-181942

Published: 2023

Journal Articles

Proteogenomic Features Define Novel Subtypes of Mantle Cell Lymphoma

Yuting Yan, Xinzhou Ge, Jian Sun, Lei Yu, Qunling Zhang, Ying Yu, Zhenyu Jia, Dehui Zou, Jessica Li, Lugui Qiu, Lili Wang, Shuhua Yi

Blood (2023) 142 (Supplement 1): 4368.

https://doi.org/10.1182/blood-2023-190838

Published: 2023

Journal Articles

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Blood (2023) 142 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2023-178710

Published: 2023

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Yuqin Song, Shuhua Yi, Haiyan Yang, Ru Feng, Huiqiang Huang, Qingyuan Zhang, Yanyan Liu, Ye Guo, Huilai Zhang, Liling Zhang, Yijiao Qian, JianKun Zhu, Jun Zhu

Blood (2023) 142 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2023-173287

Published: 2023

Journal Articles

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

Ying Yu, Yuting Yan, Jun Wang, Wenjie Xiong, Yao Yao, Yanshan Huang, Rui Lyu, Tingyu Wang, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Zhijian Xiao, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 6089.

https://doi.org/10.1182/blood-2023-188786

Published: 2023

Journal Articles

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 6140.

https://doi.org/10.1182/blood-2023-180373

Published: 2023

Journal Articles

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Mantle Cell Lymphoma in China: A Retrospective Analysis Using a Real-World Database

Yin Liu, Yanfei Chen, Ruijian Huang, Yue Xiao, Feng Jiang, Shuhua Yi, Jifang Zhou

Blood (2023) 142 (Supplement 1): 7361.

https://doi.org/10.1182/blood-2023-185803

Published: 2023

Journal Articles

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia in China: A Retrospective Analysis Using a Real-World Database

Yin Liu, Yanfei Chen, Yue Xiao, Ruijian Huang, Feng Jiang, Shuhua Yi, Jifang Zhou

Blood (2023) 142 (Supplement 1): 7360.

https://doi.org/10.1182/blood-2023-185755

Published: 2023

Journal Articles

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials

Blood (2023) 142 (Supplement 1): 1900.

https://doi.org/10.1182/blood-2023-183071

Published: 2023

Journal Articles

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Yanshan Huang, Yuting Yan, Ying Yu, Li Yuxi, Rui Lv, Tingyu Wang, Wenjie Xiong, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2023-188881

Published: 2023

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Li Yuxi, Ying Yu, Yanshan Huang, Rui Cui, Jingwen Sun, Rui Lyu, Tingyu Wang, Wenjie Xiong, Yuting Yan, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2023-186068

Published: 2023

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

Preliminary Safety, Pharmacological and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

Shuhua Yi, Jie Jin, Keshu Zhou, Huayuan Zhu, Kate Ma, Rili Jiang, Weige Wang, Bin Zhang, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6149.

https://doi.org/10.1182/blood-2023-182558

Published: 2023

Journal Articles

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 6145.

https://doi.org/10.1182/blood-2023-177820

Published: 2023

Journal Articles

Real-World Treatment Patterns, Discontinuation and Clinical Outcomes in Patients with B-Cell Lymphoproliferative Diseases Treated with BTK Inhibitors in China

Yuting Yan, Rui Lyv, Tingyu Wang, Ying Yu, Yanshan Huang, Wenjie Xiong, Gang An, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 6138.

https://doi.org/10.1182/blood-2023-188862

Published: 2023

Journal Articles

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2023-182812

Published: 2023

Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Blood (2023) 142 (Supplement 1): 3041.

https://doi.org/10.1182/blood-2023-181650

Published: 2023

Journal Articles

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Blood (2023) 142 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2023-181500

Published: 2023

Journal Articles

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Yan Xu, Gang An, Shuhui Deng, Weiwei Sui, Wei Liu, Wenyang Huang, Tingyu Wang, Shuhua Yi, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6701.

https://doi.org/10.1182/blood-2023-189353

Published: 2023

NARROW

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Proteogenomic Features Define Novel Subtypes of Mantle Cell Lymphoma

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Mantle Cell Lymphoma in China: A Retrospective Analysis Using a Real-World Database

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia in China: A Retrospective Analysis Using a Real-World Database

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Preliminary Safety, Pharmacological and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Real-World Treatment Patterns, Discontinuation and Clinical Outcomes in Patients with B-Cell Lymphoproliferative Diseases Treated with BTK Inhibitors in China

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only